Media
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
10 November 2026
Date
10 November 2026
Sustained health equity progress lifts Boehringer to rank 6th in Access to Medicine Index
The Globe and Mail covers the ranking results from the 2026 Access to Medicine Index, highlighting Boehringer Ingelheim's progress in advancing access to medicine in low- and middle-income countries, advancing to 6th place – from 8th in 2024 and 13th in 2022.
The article outlines the company's performance across three areas assessed by the Index, noting particularly strong progress in Governance of Access and Product Delivery.
It highlights a range of a range of initiatives contributing to this progress, including more comprehensive access strategies for cardio-renal-metabolic medicines, long-term partnerships and capacity-building in sub-Saharan Africa, and expanded efforts to strengthen health systems through screening, diagnostics and healthcare professional training.
It also points to the role of open innovation and stronger outcome measurement in building research capacity and assessing the reach and effectiveness of access initiatives. Â